Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts rate Fractyl Health “Hold” on average: Of five analysts, three recommend buying, one recommends holding and one recommends selling. The average 12-month price target is $5.50.
• Shares remain under pressure despite a recent 5% rise: GUTS opened at $0.59, versus a 52-week range of $0.38 to $2.44, while the company reported a quarterly loss of $0.12 per share—better than the expected $0.14 loss.
• Legal risks have intensified: Multiple law firms announced a securities class action alleging that Fractyl promoted favorable Revita DMR trial data without timely disclosing issues involving an outlier clinical-trial site; the allegations have not been proven, and October 20, 2026 is cited as the lead-plaintiff deadline.

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have received an average rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.50.

GUTS has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Weiss Ratings cut shares of Fractyl Health from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, September 3rd. Wall Street Zen downgraded shares of Fractyl Health from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Craig Hallum assumed coverage on Fractyl Health in a research note on Wednesday, July 1st. They issued a "buy" rating and a $4.00 price objective for the company.

Fractyl Health Trading Up 5.0%

Fractyl Health stock opened at $0.59 on Friday. The business has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $0.68. The company has a market cap of $94.04 million, a P/E ratio of -0.67 and a beta of 2.34. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.44. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Analysts predict that Fractyl Health will post -0.53 EPS for the current year.

Institutional Trading of Fractyl Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC raised its stake in shares of Fractyl Health by 30.1% in the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company's stock worth $13,305,000 after buying an additional 1,397,620 shares during the period. Catalio Capital Management LP increased its holdings in Fractyl Health by 5.3% in the 4th quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company's stock worth $12,082,000 after acquiring an additional 277,630 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Fractyl Health in the 2nd quarter worth approximately $8,968,058. Bank of America Corp DE bought a new stake in Fractyl Health during the 2nd quarter worth approximately $4,791,000. Finally, Atom Investors LP bought a new stake in Fractyl Health during the 4th quarter worth approximately $4,143,000.

Key Stories Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Negative Sentiment: Bronstein, Gewirtz & Grossman said a class action has been filed against Fractyl Health and certain officers, alleging investor harm. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: The complaints and related investor notices allege that Fractyl promoted positive Revita DMR weight-maintenance data for approximately a year before disclosing that an “outlier” REMAIN-1 clinical-trial site skewed the results. Some filings also allege that operational problems at the site were not timely disclosed. SueWallSt Fractyl deadline notice
• Negative Sentiment: Bernstein Liebhard, Pomerantz, Robbins, Levi & Korsinsky and other firms publicized the securities litigation, broadening investor awareness of the allegations. The proposed class generally covers investors who acquired Fractyl securities from January 13, 2025, through January 29, 2026. Pomerantz Fractyl class action announcement Robbins Fractyl shareholder notice
• Neutral Sentiment: Faruqi & Faruqi reminded investors that October 20, 2026 is the deadline to seek appointment as lead plaintiff. These announcements are legal solicitations and do not establish that Fractyl or its officers committed wrongdoing. Faruqi Fractyl lead plaintiff deadline

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company is working to address the underlying biology of these conditions and pursue treatments that may provide more durable benefits than chronic dosing alone.

Fractyl Health's technologies include the investigational Revita duodenal mucosal resurfacing (DMR) system, an endoscopic procedure designed to alter the lining of the duodenum and potentially improve metabolic control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.